Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia

(1471) Article views

Authors: Ibrahim Turkoz, Cynthia A Bossie, Bryan Dirks, Carla M Canuso

Published Date August 2008 , Volume 2008:4(5) Pages 949 - 958 DOI 10.2147/NDT.S3668

Ibrahim Turkoz, Cynthia A Bossie, Bryan Dirks, Carla M Canuso

Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA

Abstract: Direct and indirect effects of the new psychotropic paliperidone extended-release (paliperidone ER) tablets on negative symptom improvement in schizophrenia were investigated using path analysis. A post hoc analysis of pooled data from three 6-week, double-blind, placebo-controlled studies of paliperidone ER in patients experiencing acute exacerbation was conducted. Regression analysis explored relationships between baseline/study characteristics and negative symptoms. Change in Positive and Negative Syndrome Scale (PANSS) negative factor score at endpoint was the dependent variable; explanatory variables included demographic and clinical characteristics. Path analysis determined direct and indirect effects of treatment on negative symptom change. Indirect mediators of negative symptom change in the model included changes in positive symptoms, anxiety/depression symptoms and movement disorders. Path analysis indicated that up to 33% of negative symptom improvement was a direct treatment effect. Indirect effects on negative symptoms were mediated through changes in positive symptoms (51%) and anxiety/depression symptoms (18%), whereas changes in movement disorders had a 2.1% inverse effect. Path analysis indicated that paliperidone ER has a direct effect on negative symptoms. Negative symptom improvement also was indirectly mediated via changes in positive and depressive symptoms.

Keywords: antipsychotic, paliperidone ER, path analysis, psychotropic, schizophrenia